GLP-1
Results to be presented at the AASLD congress 2018, 9-13 November
Galapagos NV reports first dosing in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF).
PARAS BIOPHARMACEUTICALS FINLAND OY is currently enhancing its GMP, quality systems and production facilities for biopharmaceuticals – also known as biologics – with significant investments in new infrastructure and equipment.
Indianapolis-based Eli Lilly announced that its diabetes drug Trulicity (dulaglutide) reduced major adverse cardiovascular events (MACE) in its REWIND clinical trial.
Galapagos NV announces its unaudited Q3 results, which are further detailed in its Q3 2018 report available on the Galapagos website, www.glpg.com.
Galapagos NV announce a restructuring of their cystic fibrosis (CF) alliance; AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF.
Galapagos NV announces topline interim results of Part 1 of the FALCON trial in cystic fibrosis (CF).
Cash position of EUR 44.2 million as of September 30, 2018
What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos’ cystic fibrosis portfolio instead of walking away.
LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.
PRESS RELEASES